Certara’s Lee Stern and Shawn Bates shared their thoughts on how real world data (RWD) can be leveraged to meet health payers’ needs. Expensive novel treatments, such as those used in oncology or rare disease treatment, require a thorough understanding of the long-term costs they incur.
Stern remarks, “We’ll never have years and years and years of clinical trial data to show overall survival in, say, oncology. So, we need to leverage real-world data to extrapolate those findings from a trial into the real world and into a longer-term survival situation to reduce payer’s uncertainties about their eventual spend.” Read more here.
(Source: pharmaphorum, 11/21)